New York State Common Retirement Fund Trims Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

New York State Common Retirement Fund lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 173,639 shares of the medical equipment provider’s stock after selling 8,504 shares during the period. New York State Common Retirement Fund’s holdings in Zimmer Biomet were worth $18,341,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its position in shares of Zimmer Biomet by 165.3% during the third quarter. Blue Trust Inc. now owns 1,719 shares of the medical equipment provider’s stock worth $187,000 after acquiring an additional 1,071 shares during the period. International Assets Investment Management LLC increased its position in shares of Zimmer Biomet by 19,988.0% during the third quarter. International Assets Investment Management LLC now owns 107,471 shares of the medical equipment provider’s stock worth $11,601,000 after acquiring an additional 106,936 shares during the period. Assenagon Asset Management S.A. increased its holdings in Zimmer Biomet by 15.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 28,145 shares of the medical equipment provider’s stock worth $3,038,000 after purchasing an additional 3,859 shares during the period. Tectonic Advisors LLC increased its holdings in Zimmer Biomet by 20.8% during the 3rd quarter. Tectonic Advisors LLC now owns 3,647 shares of the medical equipment provider’s stock worth $394,000 after purchasing an additional 629 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Zimmer Biomet by 26.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,511 shares of the medical equipment provider’s stock worth $1,895,000 after purchasing an additional 3,633 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Raymond James cut their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays cut their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday, February 10th. Stifel Nicolaus raised their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Finally, JMP Securities reissued a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Up 1.2 %

NYSE:ZBH opened at $104.89 on Friday. The company has a market cap of $20.88 billion, a PE ratio of 23.57, a P/E/G ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company’s 50 day moving average is $105.86 and its two-hundred day moving average is $107.45.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.